Skip to main content
Premium Trial:

Request an Annual Quote

Kindbody Acquires Phosphorus, Plans to Adapt Lab for Fertility Testing

NEW YORK – Fertility benefits provider Kindbody said Tuesday that it has acquired genetic testing firm Phosphorus Labs. Under the agreement, the Phosphorus team will join Kindbody to form its new KindLabs division.

According to Kindbody, which owns and operates 28 US fertility clinics, Phosphorus' 8,000-square-foot New Jersey facility will allow it to begin offering its own in-house fertility-oriented genetic tests. Prior to the acquisition, Kindbody had outsourced preimplantation genetic testing and expanded carrier screening.

"With KindLabs, our patients will experience a seamless integration of high-quality genetic testing services," Kindbody CSO Dean Morbeck said in a statement. "In addition to providing an opportunity to bring existing diagnostic testing in house, KindLabs enables us to further our mission to control costs and improve patient experience and outcomes by developing and integrating new diagnostic solutions," he added.

Financial terms of the deal were not disclosed, and the companies did not detail whether Phosphorus' consumer genomics testing will continue. The firm launched an assay last year, called GeneCompass, which covers alterations in more than 400 genes related to cancer and other disease risk, drug response, and traits associated with personal health, and "wellness."


The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.